Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/30/26
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AMLGlobeNewsWire • 04/24/26
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study DataZacks Investment Research • 04/20/26
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma TranscriptSeeking Alpha • 04/17/26
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With CabozantinibGlobeNewsWire • 04/17/26
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026GlobeNewsWire • 04/09/26
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/12/26
Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to DeclineZacks Investment Research • 02/18/26
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 MilestonesGlobeNewsWire • 01/11/26
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML TranscriptSeeking Alpha • 12/08/25
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AMLGlobeNewsWire • 12/08/25
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewsWire • 12/03/25